Le marché de la thérapie par cellules souches devrait passer de 2 278,49 millions de dollars US en 2022 à 6 206,89 millions de dollars US d'ici 2028 ; on estime qu'il croîtra à un TCAC de 18,2 % de 2022 à 2028.
Les cellules souches sont des cellules corporelles préliminaires à partir desquelles toutes les autres cellules dotées de fonctions spécialisées sont générées. Dans un environnement contrôlé dans le corps ou dans un laboratoire clinique, ces cellules se divisent pour former d'autres cellules, appelées cellules filles. Avec l'avènement des sciences de la santé modernes, il a été démontré que ces cellules jouent un rôle majeur dans la compréhension de l'apparition de maladies, la génération de médicaments régénératifs avancés et la découverte d'autres médicaments. Les cellules souches se forment dans les embryons, la moelle osseuse, les graisses corporelles et le sang du cordon ombilical, entre autres.
Perspectives stratégiques
Perspectives du marché
Augmenter les produits organiques et inorganiques Stratégies des principaux acteurs
Les principaux acteurs du marché adoptent diverses stratégies organiques et inorganiques, y compris les fusions et acquisitions, les expansions et les lancements de nouveaux produits, pour rester compétitifs sur le marché.
- En octobre 2022, Medipost (PDG Won-Il Oh) a annoncé le lancement de son activité Contract Development and Manufacturing Organization (CDMO) pour les produits de thérapie cellulaire et génique en Corée. La société a annoncé que ses nouvelles installations GMP abriteront 10 salles blanches et installations de production équipées d'équipements à jour exclusivement pour le CDMO.
- En décembre 2019, Lineage Cell Therapeutics et AgeX Therapeutics, en partenariat, ont enregistré un US brevet pour la méthode de génération de cellules souches pluripotentes induites.
- En juin 2021, Allogene Therapeutics, Inc. a annoncé que la Food and Drug Administration (FDA) des États-Unis avait accordé la désignation Fast Track à ALLO-605, la société&rsquo la thérapie AlloCAR T de nouvelle génération ciblant les BCMA pour le traitement du myélome multiple récidivant ou réfractaire. La FDA a accordé la désignation Fast Track sur la base du potentiel d'ALLO-605 pour répondre au besoin non satisfait des patients qui ont échoué à d'autres traitements standard du myélome multiple.
Ainsi, de nombreuses stratégies organiques et inorganiques dans le Le marché de la thérapie par cellules souches permet aux professionnels de la santé de fournir des services améliorés.
Régions lucratives sur le marché de la thérapie par cellules souches
(image) La thérapie par cellules souches a été largement étudiée à travers le monde. Les cellules souches sont principalement utilisées pour remplacer les cellules mourantes et reconstruire les tissus endommagés. Sur la base des résultats des recherches approfondies sur les cellules souches menées jusqu'à présent, de nombreux scientifiques ont affirmé que ces cellules pourraient probablement être utilisées pour générer des remèdes et des traitements pour des maladies telles que le cancer et les maladies cardiovasculaires. Les thérapies à base de cellules souches nouvellement développées consistent à remplacer les cellules pathogènes par des cellules souches. De nombreux traitements potentiels impliquant des cellules souches sont à différentes phases d'essais cliniques. La FDA a également approuvé quelques thérapies à base de cellules souches impliquées dans le traitement des complications liées aux greffes de cellules souches. En septembre 2021, la Food and Drug Administration (FDA) des États-Unis a annoncé l'approbation du « ruxolitinib » pour le traitement de la « maladie du greffon contre l'hôte » (GVHD) chez les patients âgés de 12 ans et plus. Le ruxolitinib offre un nouvel espoir à un patient qui souffre de complications mortelles associées aux greffes de cellules souches.
Les chercheurs étudient plus avant l'utilisation de la thérapie par cellules souches dans le traitement des maladies auto-immunes. Par exemple, les cellules souches peuvent se transformer en cellules d'organes endommagés et sont utilisées dans le traitement des maladies auto-immunes. Le traitement est effectué à l'aide de cellules souches mésenchymateuses ou de cellules souches ftales. Les cellules souches hématopoïétiques sont actuellement utilisées pour traiter plus de 80 conditions médicales, y compris les maladies du système immunitaire ; troubles sanguins; troubles neurologiques; Troubles métaboliques; les troubles génétiques; et les types de cancer tels que la leucémie et le lymphome.
Type Insights
En fonction du type, le marché de la thérapie par cellules souches est segmenté en thérapie par cellules souches adultes, thérapie par cellules souches pluripotentes induites, thérapie par cellules souches embryonnaires thérapie cellulaire et autres thérapies par cellules souches. Le segment de la thérapie par cellules souches adultes détenait la plus grande part de marché en 2021. Cependant, le segment de la thérapie par cellules souches pluripotentes induites devrait enregistrer le TCAC le plus élevé au cours de la période de prévision (2022-2028).
Perspectives sur le traitement< /h3>
Sur la base du traitement, le marché mondial de la thérapie par cellules souches est divisé en allogénique et autologue. Le segment allogénique détenait la plus grande part de marché de la thérapie par cellules souches en 2021. De plus, le segment autologue devrait croître au TCAC le plus élevé au cours de la période de prévision.
Application Insights
En termes d'application, le marché de la thérapie par cellules souches est divisé en applications musculo-squelettiques, dermatologie, cardiologie, découverte et développement de médicaments et autres applications. Le segment de la découverte et du développement de médicaments détenait la plus grande part de marché en 2021, et il devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Marché de la thérapie par cellules souches, par type &ndash ; 2021 et 2028
(image)
Perspectives de l'utilisateur final
Sur la base de l'utilisateur final, le marché de la thérapie par cellules souches est divisé en académique & instituts de recherche et hôpitaux & cliniques. L'universitaire & Le segment des instituts de recherche détenait une plus grande part de marché en 2021, et le même segment devrait enregistrer un TCAC plus élevé sur le marché au cours de la période de prévision (2022-2028).
Les entreprises du marché de la thérapie par cellules souches adoptent majoritairement stratégies inorganiques telles que les fusions et acquisitions. Quelques-uns des développements clés récents sur le marché sont énumérés ci-dessous.
- En juin 2021, l'USFDA a accordé la désignation Fast Track à ALLO-605, la nouvelle génération Thérapie AlloCAR T proposée par Allogene Therapeutics, Inc., ciblant la BCMA pour le traitement du myélome multiple récidivant ou réfractaire. La désignation a été accordée sur la base du potentiel d'ALLO-605 pour répondre aux besoins non satisfaits des patients qui n'ont pas répondu aux autres traitements standard du myélome multiple.
- En juin 2021, MEDIPOST a annoncé que la société avait a agrandi les installations de production de ses produits à base de cellules souches pour l'arthrose du genou, CARTITEM et SMUP-IA-01, et commencera à se préparer à la certification GMP (Good Manufacturing Practice).
- En septembre 2022, Caladrius Biosciences, Inc. et Cend Therapeutics, Inc. a annoncé que le projet de fusion des deux sociétés a été clôturé suite à l'approbation de Caladrius’ actionnaires le 13 septembre 2022. La société fusionnée opérera sous le nom de Lisata Therapeutics, Inc. et se concentrera principalement sur l'avancement de ses produits candidats de la technologie CendR Platform dans une gamme d'indications oncologiques, en plus de Caladrius’ programmes de développement existants.
- En mars 2019, BioTime, Inc. a acquis Asterias Biotherapeutics, Inc. qui s'occupe de médicaments régénératifs afin de consolider son portefeuille de produits de thérapies à base de cellules souches.
Entreprise Profils
- MEDIPOST
- Pharmicell Co., Inc.
- RichSource
- BioTime, Inc.
- Mesoblast Limited
- Holostem Terapie Avanzate Srl
- US Stem Cell, Inc.
- Caladrius Biosciences, Inc.
- TiGenix NV
- AlloSource
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated.
Increasing research activities related to stem cell therapy for effective disease management and growing prevalence of cancer are the most significant factors responsible for the overall market growth.
Based on type segment, the adult stem cell therapy segment took the forefront leaders in the worldwide market by accounting largest share in 2021 and is expected to continue to do so till the forecast period.
Based on the treatment, allogenic segment took the forefront leaders in the worldwide market by accounting largest share in 2021.
Academic & Research institutes segment dominated the global stem cell therapy market and accounted for the largest market share during the forecast period of 2022-2028.
MEDIPOST, RichSource, BioTime, Inc., Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., TiGenix NV, AlloSource, NuVasive Inc, JCR Pharmaceuticals Co. Ltd. and among others are among the leading companies operating in the stem cell therapy market.
Global stem cell therapy market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.
The List of Companies - Stem Cell Therapy Market
- MEDIPOST
- RichSource
- BioTime, Inc.
- Mesoblast Limited
- Holostem Terapie Avanzate Srl
- U.S. Stem Cell, Inc.
- TiGenix NV
- AlloSource
- NuVasive Inc
- JCR Pharmaceuticals Co. Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Feb 2023
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Feb 2023
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2023
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Feb 2023
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Feb 2023
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Feb 2023
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Feb 2023
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)